China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinical trials.
The video platform said it would now ban any content with claims about COVID-19 vaccines that contradict consensus from local health authorities or the World Health Organization.
The alliance is designed so that richer countries agree to buy into potential vaccines and help finance access for poorer ones. "The goal of COVAX is by the end of 2021 to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification. These vaccines will be delivered equally to all participating countries, proportional to their populations," according to the World Health Organisation.
Facing a White House blockade, the Food and Drug Administration is seeking other avenues to ensure that vaccines meet the guidelines. That includes sharing the standards — perhaps as soon as this week — with an outside advisory committee of experts that is supposed to meet publicly before any vaccine is authorized for emergency use.
According to a report by Reuters, one of China's front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG).
Officials in Jiaxing city said Thursday residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine that authorities have been giving to groups such as medical workers.
The peptide-based, two-shot vaccine, EpiVacCorona, was developed by the Vector Institute in Siberia and tested among 100 volunteers in early-stage, placebo-controlled human trials, which lasted more than two months and were completed two weeks ago.
The U.S. Food and Drug Administration has said it will not approve a vaccine unless it is both effective and safe. On Tuesday, it added more stringent safety guidelines for U.S. vaccines.
There were several developments regarding vaccines and drugs this week, including the tie-up between the makers of Russia’s Sputnik V vaccine and Dr Reddy’s.
"A wild ride indeed and one that is likely to continue as phase 3 vaccine results starts to roll through over the coming weeks," NAB analyst Tapas Strickland said in a note on Monday.
The Group of Ministers (GoM) meeting is underway in the national capital on October 13. Health Minister Dr Harsh Vardhan said, “We are expecting that early next year we should have vaccine in the country from maybe more than one source.” “Our expert groups are formulating strategies to plan on how to roll out the distribution of the vaccine in the country,” he added. India will have COVID vaccine early next year from more than one source: Harsh Vardhan
PM Modi said India was putting in place a well-established vaccine delivery system, through a digitised network along with the digital health ID, for the immunisation of citizens.
WHO chief scientist Soumya Swaminathan said in Geneva this month that national regulatory authorities could approve use of medical products within their own jurisdictions in the current emergency situation, but described that as a "temporary solution".
In India, Prime Minister Narendra Modi’s government had promised an indigenous vaccine as early as mid-August, a claim the government and its apex medical research body has since walked back.
“Nationally, nearly 30 Covid-19 vaccine candidates are under development, by both industry and academia. These vaccines are in different stages of pre-clinical and clinical development,” said Harsh Vardhan, Union Minister for Health and Family Welfare, in the Lok Sabha last week.
Polls are finding Americans increasingly wary of accepting a coronavirus vaccine. And scientists inside and outside the government are worried that regulators, pressured by the president for results before Election Day on Nov. 3, might release an unproven or unsafe vaccine.
A government expert group on vaccines, which is looking into the procurement of Covid-19 vaccines — made in India and abroad — and the guiding principles for prioritisation of population groups for vaccination, has proposed setting up a digital platform to track procurement and record administration.
Many of the vaccines at the front of the pack today try to teach the body the same basic lesson. They deliver a protein that covers the surface of the coronavirus, called spike, which appears to prompt the immune system to make antibodies to fight it off. But some researchers worry that we may be pinning too many hopes on a strategy that has not been proved to work.
China has four COVID-19 vaccines in the final stage of clinical trials. At least three of those have already been offered to essential workers under an emergency use programme launched in July.
The European Commission announced on Wednesday it has reached a deal with a sixth pharmaceutical firm, this time BioNTech-Pfizer, to reserve a further 200 million doses of a potential coronavirus vaccine.
The issue is also likely to come up during foreign minister S Jaishankar's visit to Moscow this week. The Russian ambassador, Nikolay Kudashev also said though that Russia hoped to work with India for a "just and multipolar" world order at a time some countries were playing "geopolitical games" despite the pandemic and creating "close-door exclusive blocs".
From factory to syringe, the world's most promising coronavirus vaccine candidates need non-stop sterile refrigeration to stay potent and safe.
Russia has said the vaccine, developed by Moscow's Gamaleya Institute and the first for the coronavirus to go into production, will be rolled out by the end of this month.
The vaccine candidate under trial by University of Oxford scientists in collaboration with pharmaceutical giant AstraZeneca is the furthest in the process of trials and, according to a report in ‘The Times', it could be given the required clearances by Christmas in December.
This special COVID-19 immunisation programme would run in parallel with the Universal Immunisation Programme, but will use its processes, technology and network of the existing vaccine distribution framework, sources said.
The United Kingdom this week announced that it has signed a deal for the first ‘human challenge’ trials, where healthy volunteers will be exposed to the SARS-Cov2, the virus that causes Covid-19. Why is the UK doing this? How does this help fight the pandemic and what are the ethical challenges of this approach? Divya Rajagopal reports on the unique nature of these trials
"WHO is working on an allocation policy for Covid-19 vaccines and has proposed that the goal of vaccination should be to minimise the societal and economic impact by reducing Covid-19 mortality," said Poonam Khetrapal Singh, regional director, South-East Asia Region, WHO.
Early in August, the Russians announced that they had successfully created a vaccine against the coronavirus, even as competitors remained in trial stages, with no products expected till 2021.
The World Health Organization (WHO) said nine vaccines are being evaluated by its cooperative COVAX facility which now has 172 nations as contributing partners. The COVAX program was established earlier this year by the WHO and is designed to pool the efforts of member nations to guarantee equitable access globally to any COVID-19 vaccines, as well as other COVID treatments, once they are developed and authorized for use. COVAX program is evaluating nine potential coronavirus vaccines: WHO
Govt eyes 50 lakh doses of Covid vaccine in 1st order for front-line workers, army personnel and certain other categories
The prioritisation of the vaccine once it passes regulatory requirements and becomes available has been under discussion in government along with planning supply chains and distribution.
I do not think it is going to be anything like what we had in February and March, says Geoff Dennis.
China is in a global race to develop cost-effective vaccines to curb the COVID-19 pandemic. Using insect cells to grow proteins for the coronavirus vaccine - a first in China - could speed up large-scale production, the city government of Chengdu said in a notice on social media WeChat.
While China wasn’t on the list, 38 governments are expected to sign up in the coming days, according to a statement Monday from Gavi, the Vaccine Alliance. The group is leading the effort, Covax, along with the World Health Organization and the Coalition for Epidemic Preparedness Innovations. The U.S. has said it won’t participate.
Clinical trials experts said these delays were comforting, in a way: They show that the researchers were following proper safety procedures. But for now, details about the nature of the volunteers’ illnesses are scant. And although pauses of vaccine trials are not unusual, some experts said that pausing treatment trials — like that of Eli Lilly’s antibody drug — is rarer and perhaps more worrisome.
Pune based Serum Institute of India (SII) that is conducting Phase 3 trial of the Oxford Covid-19 vaccine has approached India’s drug regulator seeking approval for changes to its protocol to broaden the horizon of the trials.
The head of Germany's vaccines regulator said some groups of people living in Germany could be vaccinated early next year against the coronavirus that has killed almost 800,000 worldwide and wreaked havoc on the global economy.
Initial study shows that the Oxford-AstraZeneca vaccine for Covid-19 triggers antibody response and is safe. ET’s Divya Rajagopal gives an in-depth analysis of the vaccine which will go on trial in India soon. WatchOxford University Coronavirus vaccine: Why it raises hope
Adding that the platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”
"We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of COVID-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration," said Managing Director of BE, Mahima Datla.
The world has not seen any data on Phase 1 or 2 clinical trials conducted by Moscow-based Gamaleya Research Institute, the Executive Chairperson of Bengaluru-headquartered Biocon Ltd said. "But it doesn't make them the world's first vaccine as several other vaccine programmes are even more advanced," she added.
The company has already approached the states for initiating phase III trials this month. As reported by ET earlier, the company has written to various states including Delhi, Uttar Pradesh, Bihar, Maharashtra, Punjab and Assam, seeking their permission and facilitation to initiate the trial.
Russia has approved a coronavirus vaccine but the World Health Organisation is wary of it. "We are in close contact with Russian health authorities and discussions are ongoing with respect to possible WHO prequalification of the vaccine, but again prequalification of any vaccine includes the rigorous review and assessment of all required safety and efficacy data," WHO spokesman Tarik Jasarevic told.WHO in contact with russia on new coronavirus vaccine Sputnik V
Russia on Tuesday became the first country to approve a coronavirus vaccine, a move that was met with international skepticism and unease because the shots have only been studied in dozens of people.
A national expert group is talking to public and private sector entities in the pharmaceutical sector, food processing industry and agro businesses as well as food delivery start-ups such as Swiggy and Zomato to identify cold storages or fridges at the taluka level that can stock and distribute the vaccine.
Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so,” the company said in a statementOxford’s coronavirus vaccine AstraZeneca trial resumes after UK green signal
"The vaccine developed by the Gamaleya centre will be registered on August 12. At the moment, the last, third, stage is underway. The trials are extremely important. We have to understand that the vaccine must be safe. Medical professionals and senior citizens will be the first to get vaccinated," Gridnev told reporters at the opening of a cancer centre building in the city of Ufa.
Asked by radio talk show host Geraldo Rivera whether a vaccine could come by the election, Trump said: "I think in some cases, yes, possible before. But right around that time." Trump said the vaccine would be ready "sooner than the end of the year. Could be much sooner."
In a letter to the Bangladesh government on September 22, Beijing headquartered Sinovac Biotech said the phase 3 trials of the vaccine they are developing would be delayed until the Bangladesh government co-finances the testing initiative.
Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the Bangladesh government provided funds, although the company was supposed to bear the costs as per an agreement. The Beijing-based vaccine giant sent the letter to the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), which was to conduct the trial.
Clinical trial of Sputnik V Coronavirus vaccine to begin this month in countries including India: RDIF
Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.
The country is pushing ahead with several vaccine prototypes and one trialled by the Gamaleya institute in Moscow has reached advanced stages of development and is about to pass state registration, officials said. "We are very much counting on starting mass production in September," Industry Minister Denis Manturov said.
Although international groups and a number of nations are promising to make vaccines affordable and accessible to all, doses will likely struggle to keep up with demand in a world of roughly 7.8 billion people. The possibility wealthier countries will monopolize supply, a scenario that played out in the 2009 swine flu pandemic, has fueled concerns among poor nations and health advocates.
The coronavirus pandemic has prompted one of the fastest peacetime mission shifts in recent times for the world’s intelligence agencies, pitting them against one another in a new grand game of spy versus spy, according to interviews with current and former intelligence officials and others tracking the espionage efforts.
Human challenge study in the development of a vaccine refers to exposing healthy volunteers to a pathogen and then monitoring them in a clinical setting to see how they react to the virus. The challenge trial becomes controversial in settings where there is no proven treatment or cure for an infectious disease. Covid-19 is one such disease.
The drug developed by Moscow’s Gamaleya Institute and the Russian Direct Investment Fund may be approved for civilian use within three to seven days of registration by regulators, according to a person familiar with the process, who asked not to be identified because the information isn’t public.
The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine's safety in older adults, a group at increased risk of severe complications from COVID-19.
"In many ways, cancer behaves like a virus, so our team decided to use the tools we developed to identify unique aspects of childhood cancers that can be targeted with immunotherapies and apply those same tools to identify the right protein sequences to target in SARS-CoV-2," said John M Maris, a pediatric oncologist, and a professor at the University of Pennsylvania.
ET takes a look at how the European Union, the Unites States, other OECD nations, and, more importantly, India are placed in the race to secure vaccine supplies.
In reference to the vaccine being worked on by the University of Oxford, Johnson stressed the importance of equitable access of any successful vaccine because the health of every country depends on the whole world having access to a safe and effective vaccine, wherever a breakthrough might occur.
Already stretched thin by the pandemic, freight companies face problems ranging from shrinking capacity on container ships and cargo aircraft to a lack of visibility on when a vaccine will arrive.
Salmon and other experts said that Russia is taking a dangerous step by jumping ahead of so-called Phase 3 trials, which can determine that the vaccine works better and doesn’t cause harm to people.
Speaking at a government meeting on Tuesday, Vladimir Putin said that the vaccine has proven efficient during tests, offering a lasting immunity from the coronavirus.
The hackers, identified as Li Xiaoyu and Dong Jiazhi, stole information not only for their personal profit but also research and technology that they knew would be of value to the Chinese government, prosecutors say.
Spain, which has western Europe's highest tally of coronavirus cases, is also working with AstraZeneca via the European Union's vaccine procurement programme to secure sufficient doses. J&J's website says if the latest trials are successful, it will begin final Phase III studies, in which even more volunteers will receive the experimental vaccine.
Li Xiaoyu, 34, and Dong Jiazhi, 33, also targeted human rights activists in the United States, China and Hong Kong, US Assistant Attorney General for National Security John Demers said. The hackers, who are believed to be in China beyond the reach of US law enforcement, acted in some instances "for their own personal gain" and in others for the benefit of China, he added.
The trial data of a COVID-19 vaccine developed by AstraZeneca and Oxford University reveals that it is safe and induces immune response, with mild side effects in some participants, scientists announced on Monday.
Producing vaccines and deploying them to the world’s population in the midst of a pandemic would be a massive challenge even if researchers are able to deliver one-dose inoculations. A need for two would make manufacturing and logistics even more complex.
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are designed to evaluate safety and see what kind of immune response was provoked, but can't tell if the vaccine truly protects.
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.
A huge international study of a COVID-19 vaccine that aims to work with just one dose is getting underway as top U.S. health officials sought Wednesday to assure a skeptical Congress and public that they can trust any shots the government ultimately approves. Hopes are high that answers about at least one of several candidates being tested in the U.S. could come by year's end, maybe sooner.Single-dose COVID vaccine tested, experts assure 'no corners cut' at US Congress hearing
A wide range of symptoms and severity makes the evaluation of Covid-19 vaccines tricky. The U.S. Food and Drug Administration has said that to be approved, vaccines should cut the number of symptomatic cases by half. Yet documents released by the drugmakers show each has its own approach to defining which symptoms count, and when to count them.
Our innovation pipeline will come to post a 3-5-year timeframe. In the three-year timeframe, there is a possibility to launch one or two products if the clinical trials are successful, says Co-Chairman & MD, Dr Reddy's.GV Prasad of Dr Reddy's on Russian vaccine, Remlivid settlement & more
China has positioned itself to be a strong contender. Eight of the nearly two dozen potential vaccines in various stages of human testing worldwide are from China, the most of any country. And SinoPharm and another Chinese company already have announced they're entering final testing.
As the toll from COVID-19 keeps rising, both across the world and in India, the pressure to formulate a vaccine has never been greater. Here's a look at all the companies that are making headway.
Public-health officials, epidemiologists, amateur observers and others have watched as the pandemic has unfolded, looking for how to measure the virus’s deadliness. Tallying deaths as a percentage of the greater population sheds light on the scope of the pandemic. Excess mortality compares fatalities to what the death rate is expected to be.
After much fanfare over vaccine, there is now an inexplicable lull in Russia. The reasons are unknown
The Russian vaccine is one of the nine candidates around the world now in the late-stage clinical trials that are the only sure means to determine whether a vaccine is effective and find possible side effects.
He said "brilliant" doctors and scientists of the US have been working around the clock to produce a COVID-19 vaccine and informed that three vaccines are in the final stage of clinical trials.
Companies typically share these documents after their studies are complete. The disclosures while the trials are still underway, a rare move, are aimed at addressing growing suspicion among Americans that President Donald Trump’s drive to produce a vaccine before the election on Nov. 3 could result in a product that was unsafe.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund has tied up with India's Dr Reddy’s Laboratories to conduct the clinical trials and distribution of Sputnik V vaccine in India. ET’s Divya Rajagopal caught up with CEO RDIF, Kirill Dmitriev to understand when the vaccine will be available in India. WatchWith approvals Sputnik V delivery in India possible by end of 2020: Kirill Dmitriev, CEO, RDIF
Two injections of the vaccine protected against heavy exposure to the virus at two different levels of dosage, Moderna said in findings published Tuesday in the New England Journal of Medicine.
'World suffering from China virus, will soon achieve victory': Trump on Coronavirus vaccine progress
US President Donald Trump visited North Carolina Monday to tout the rapid progression of possible vaccines to treat coronavirus. Trump said, "We will achieve a victory over the virus by unleashing America's scientific genius, which is what it is. I am therefore proud to announce that this morning the Moderna, a vaccine has officially entered Phase three already." "We're mass-producing all of the most promising vaccine candidates in advance, so that on the day one that it's approved, it'll be available to the American people immediately and we'll probably have a lot for a lot of other people throughout the world. The world is suffering from this China virus," Trump further added.'World suffering from China virus, will soon achieve victory': Trump on Coronavirus vaccine progress
British scientists are beginning a small study comparing how two experimental coronavirus vaccines might work when they are inhaled by people instead of being injected.
Both BB and Zydus were granted permission for Phase I and II clinical trials and administered the first doses of their vaccine candidates to volunteers on July 15. A third vaccine candidate, developed by Oxford University, is soon to be tested in India. Serum Institute, which is in a manufacturing partnership with the UK’s Astra Zeneca, has said it will begin human trials as soon as it receives regulatory approval.
Russia has named its first approved coronavirus vaccine 'Sputnik V' for the foreign markets. It is a reference to the world's first satellite Sputnik and what Moscow sees as its success at becoming the first country to approve a vaccine, a top official said.Russia names its coronavirus vaccine as 'Sputnik V' in reference to world's first satellite
As the Oxford-AstraZeneca's COVID-19 vaccine gains momentum after showing positive results in the initial trials, Serum Institute of India, headed by Adar Poonawalla is all set to conduct trials for the vaccine in India, and begin production of the doses as well. In an exclusive conversation with TIMES NOW's Swati Joshi, Adar Poonawalla talked about Oxford COVID-19 vaccine, its effectiveness and availability, Bharat Biotech-ICMR controversy and more. Listen-in!!!Oxford COVID vaccine likely to hit Indian market by early 2021: Serum Institute's CEO Poonawalla
Novavax will inject 131 volunteers in the first phase of the trial testing the safety of the vaccine and looking for signs of its effectiveness, the company's research chief Dr. Gregory Glenn said.
UK-based biopharma giant AstraZeneca has said that the phase 3 testing of its COVID-19 vaccine being developed with Oxford University has been put on hold, due to a suspected serious adverse reaction in a participant in the United Kingdom. The vaccine, which AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization (WHO) as probably the world's leading candidate and the most advanced in terms of development.AstraZeneca pauses COVID-19 vaccine trial in UK due to unexplained illness of participant
The royal looked at a laboratory where samples from the clinical trial were being examined by researchers.
The Dow Jones Industrial Average was up 767.76 points, or 3.24 per cent, at 24,453.18.
Enlisting the nominal aid of fictional sleuths to solve coronavirus mysteries.
Each of these experimental vaccines has already shown promise in smaller trials designed to flag any serious safety concerns and show whether candidates can spur some response from the immune system. Early safety data is key; unlike drugs, vaccines are typically given to relatively healthy people and shouldn’t create severe risks.
According to the minutes of the meeting, the SEC has asked Serum to distribute clinical trial sites pan India, demarcate the phase II and Phase III part of the protocol. ET has seen the minutes of the meeting.
The leading infectious diseases expert Dr. Anthony Fauci said Tuesday the development of a vaccine for the coronavirus was moving at rapid speed because of "the urgency of the situation." Fauci, the director of the National Institute of Allergy and Infectious Diseases, urged people to wear masks and to follow social distancing guidelines. White House health advisor said the coronavirus pandemic is the worst seen in over a century.Worst pandemic in century, coronavirus vaccine development moving at rapid speed: Dr. Anthony Fauci
With the entire world grappling with COVID-19 and global hospital infrastructure struggling to cope with the massive toll, the race for a vaccine is heating up, and some countries have made breakthroughs.
Sanofi is working on two vaccine projects to prevent COVID-19 - the illness caused by the new coronavirus - and said it is exploring several manufacturing options, including fresh collaborations to ensure it can meet demand, if either program is successful.
The Vaccine Task Force set up earlier in April is co-chaired by Paul and Vijay Raghavan and met on April 16 and April 20 to approve the decisions.
The change appears aimed at convincing governments which have negotiated their own bilateral deals securing experimental vaccines to also sign up for the global COVAX facility by Monday's deadline for submitting expressions of interest.
The US and other superpowers have laid claim to billions of Covid vaccine doses that are nearing the finish line. That’s sparked worries that poorer countries will be left behind and shots will be slow to reach many of them. Dozens of laboratories, researchers and companies from Thailand to Nigeria are bootstrapping their own work on inoculations.
A scarcity of laboratories equipped to handle necessary tests and meet all safety requirements may delay trials of potential Covid-19 vaccines in India, some vaccine developers said.
The vaccine candidate has been developed by the Jenner Institute, a part of the Nuffield Department of Medicine at the University of Oxford. The formulation is backed by AstraZeneca PLC, a British-Swedish pharmaceutical company.